The role of circulating tumor DNA in ovarian cancer
Blood tests for cancer DNA show promise for detecting ovarian cancer recurrence earlier and personalizing therapy, though technical hurdles remain before routine clinical use.
This review synthesizes current evidence on ctDNA applications in ovarian cancer, covering early screening, MRD monitoring, recurrence prediction, and therapy personalization, positioning ctDNA as superior to CA-125 and conventional markers. Technical challenges in early-stage detection sensitivity and assay standardization remain as barriers to clinical implementation.
What the study was
- Study design
- Narrative review
- Population
- Ovarian cancer patients
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Discov Oncol
Why it surfaced
Review consolidating ctDNA in ovarian cancer — relevant background for pipeline. No new primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.